Briefwechsel der königin Katharina und des königs Jérome von Westphalen, sowie des kaisers Napoleon I,

v. 1. Vom. 8. Oktober 1801 bis 22. Dezember 1810.--v.2. Vom 20. März 1811 bis 27. September 1816.--v. 3. Nachtrag zu band I und II aus dem Napoleon'schen hausarchive.

Der Briefwechsel zwischen der Kaiserin Katharina II. von Russland und Joh. Georg Zimmermann.

Mode of access: Internet.

Die polnischen Provinzen Russlands unter Katharina 2. in den Jahren 1772-1782. Versuch einer Darstellung der anfänglichen Beziehungen der russischen Regierung zu ihren polnischen Untertanen. Aus dem finnischen original übersetzt von Gustav Schmidt.

Includes bibliographical references.

Katharina II,

Mode of access: Internet.

Zur geschichte der legende der Katharina von Alexandrien,

Critical Study of Greek & Latin texts on the legend of St. Catherine of Alexandria (4th century).

Filip van Marnix, heer van St. Aldegonde, bijzonder aan de hand van Willem I : ter inleiding Margareta van Parma en Katharina de Medicis, Willem I en Hendrik IV /

Mode of access: Internet.

Katharina II, Kaiserin von Russland im Urtheile der Weltliteratur.

Translation of the concluding volume of his: Istoriia Ekateriny Vtoroĭ.

Katharina Mangold / Claudia Muche / Sabrina Volk: Educational Mix in der frühen Kindheit. Regionale Dienstleistungsinfrastrukturen im Vergleich. Weinheim und Basel: Beltz Juventa 2013 (212 S.) [Rezension]

Rezension von: Katharina Mangold / Claudia Muche / Sabrina Volk: Educational Mix in der frühen Kindheit. Regionale Dienstleistungsinfrastrukturen im Vergleich. Weinheim und Basel: Beltz Juventa 2013 (212 S.; ISBN 978-3-7799-2819-5)

The cost-effectiveness of routine follow-up after primary total hip arthroplasty

Routine postsurgery assessment of primary total hip arthroplasty (THA) is recommended in many countries. Whether the benefits of this activity are justified by the costs is not known. We used a decision-analytic Markov model to compare the costs and health outcomes of 3 different follow-up strategies after primary THA. If there is no routine follow-up of patients for 7 years after primary THA, there would be cost savings between AU$6.5 and $11.9 million and gains of between 1.8 and 8.8 quality-adjusted life years. Policy makers should investigate less resource-intensive alternatives to common routine postsurgical assessment.

Brain-derived neurotrophic factor (BDNF) gene : no major impact on antidepressant treatment response

The brain-derived neurotrophic factor (BDNF) has been suggested to play a pivotal role in the aetiology of affective disorders. In order to further clarify the impact of BDNF gene variation on major depression as well as antidepressant treatment response, association of three BDNF polymorphisms [rs7103411, Val66Met (rs6265) and rs7124442] with major depression and antidepressant treatment response was investigated in an overall sample of 268 German patients with major depression and 424 healthy controls. False discovery rate (FDR) was applied to control for multiple testing. Additionally, ten markers in BDNF were tested for association with citalopram outcome in the STAR*D sample. While BDNF was not associated with major depression as a categorical diagnosis, the BDNF rs7124442 TT genotype was significantly related to worse treatment outcome over 6 wk in major depression (p=0.01) particularly in anxious depression (p=0.003) in the German sample. However, BDNF rs7103411 and rs6265 similarly predicted worse treatment response over 6 wk in clinical subtypes of depression such as melancholic depression only (rs7103411: TT

Knowledge about health benefits of Vitamin D in Queensland Australia

In Queensland, Australia, the ultraviolet (UV) radiation levels are high (greater than UV Index 3) almost all year round. Although ambient UV is about three times higher in summer compared to winter, Queensland residents receive approximately equal personal doses of UV radiation within these seasons (Neale et al., 2010). Sun protection messages throughout the year are thus essential (Montague et al., 2001), need to reach all segments of the population, and should incorporate guidelines for maintenance of adequate vitamin D levels. Knowledge is an essential requirement to allow people to make health conscious decisions. Unprompted knowledge commonly requires a higher level of awareness or recency of acquisition compared to prompted recall (Waller et al., 2004). This paper thus reports further on the data from a 2008 population-based, cross-sectional telephone survey conducted in Queensland, Australia (2,001 participants; response rate=45%) (Youl et al., 2009). It was the aim of this research to establish the level of, and factors predicting, unprompted and prompted knowledge about health and vitamin D.

Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma

Objective Uterine Papillary Serous Carcinoma (UPSC) is uncommon and accounts for less than 5% of all uterine cancers. Therefore the majority of evidence about the benefits of adjuvant treatment comes from retrospective case series. We conducted a prospective multi-centre non-randomized phase 2 clinical trial using four cycles of adjuvant paclitaxel plus carboplatin chemotherapy followed by pelvic radiotherapy, in order to evaluate the tolerability and safety of this approach. Methods This trial enrolled patients with newly diagnosed, previously untreated patients with stage 1b-4 (FIGO-1988) UPSC with a papillary serous component of at least 30%. Paclitaxel (175 mg/m2) and carboplatin (AUC 6) were administered on day 1 of each 3-week cycle for 4 cycles. Chemotherapy was followed by external beam radiotherapy to the whole pelvis (50.4 Gy over 5.5 weeks). Completion and toxicity of treatment (Common Toxicity Criteria, CTC) and quality of life measures were the primary outcome indicators. Results Twenty-nine of 31 patients completed treatment as planned. Dose reduction was needed in 9 patients (29%), treatment delay in 7 (23%), and treatment cessation in 2 patients (6.5%). Hematologic toxicity, grade 3 or 4 occurred in 19% (6/31) of patients. Patients' self-reported quality of life remained stable throughout treatment. Thirteen of the 29 patients with stages 1–3 disease (44.8%) recurred (average follow up 28.1 months, range 8–60 months). Conclusion This multimodal treatment is feasible, safe and tolerated reasonably well and would be suitable for use in multi-institutional prospective randomized clinical trials incorporating novel therapies in patients with UPSC.